Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.80    -2.40 (-1.79%)
Bid:
131.40
Ask:
132.20
Spread: 0.80 (0.609%)
Market Cap: £320.83m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Transaction in Own Shares

17 Aug 2022 07:00

RNS Number : 2413W
PureTech Health PLC
17 August 2022
 

17 August 2022

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

16 August 2022

Number of ordinary shares purchased:

12,947

Highest price paid per share:

242.50p

Lowest price paid per share:

241.00p

Volume weighted average price paid per share:

242.34p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 4,369,136 ordinary shares in treasury and has 284,320,314 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 284,320,314, which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules. 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders.

This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

 

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

16/08/2022

11:21:34

5

241.5

XLON

00313214401TRLO1.1.1

16/08/2022

11:21:34

5

241.5

TRQX

00313214400TRLO1.1.1

16/08/2022

11:18:20

61

242

CHIX

00313214029TRLO1.1.1

16/08/2022

11:17:32

42

242.5

BATE

00313213954TRLO1.1.1

16/08/2022

11:17:32

42

242.5

BATE

00313213953TRLO1.1.1

16/08/2022

11:16:17

104

241.5

XLON

00313213808TRLO1.1.1

16/08/2022

11:16:17

56

242

CHIX

00313213807TRLO1.1.1

16/08/2022

11:01:00

15

242.5

BATE

00313211880TRLO1.1.1

16/08/2022

11:00:59

34

242.5

BATE

00313211878TRLO1.1.1

16/08/2022

11:00:58

5

241.5

TRQX

00313211876TRLO1.1.1

16/08/2022

11:00:58

410

241.5

XLON

00313211875TRLO1.1.1

16/08/2022

11:00:58

30

242

AQXE

00313211874TRLO1.1.1

16/08/2022

11:00:58

24

242.5

AQXE

00313211873TRLO1.1.1

16/08/2022

11:00:57

60

242

CHIX

00313211872TRLO1.1.1

16/08/2022

11:00:57

1

242

TRQX

00313211870TRLO1.1.1

16/08/2022

11:00:57

2

242

TRQX

00313211869TRLO1.1.1

16/08/2022

11:00:57

54

242

CHIX

00313211871TRLO1.1.1

16/08/2022

11:00:57

2

242

TRQX

00313211868TRLO1.1.1

16/08/2022

11:00:57

476

242

XLON

00313211867TRLO1.1.1

16/08/2022

11:00:57

476

242.5

XLON

00313211866TRLO1.1.1

16/08/2022

10:56:15

370

242

XLON

00313210802TRLO1.1.1

16/08/2022

10:54:24

6

242

TRQX

00313210345TRLO1.1.1

16/08/2022

10:54:24

50

242

CHIX

00313210344TRLO1.1.1

16/08/2022

10:54:24

428

242.5

XLON

00313210343TRLO1.1.1

16/08/2022

10:54:24

445

242.5

XLON

00313210342TRLO1.1.1

16/08/2022

10:54:24

489

242.5

XLON

00313210341TRLO1.1.1

16/08/2022

10:54:24

435

242.5

XLON

00313210340TRLO1.1.1

16/08/2022

10:54:24

441

242.5

XLON

00313210339TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210337TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210338TRLO1.1.1

16/08/2022

10:54:24

414

242.5

XLON

00313210335TRLO1.1.1

16/08/2022

10:54:24

517

242.5

XLON

00313210336TRLO1.1.1

16/08/2022

10:54:24

482

242.5

XLON

00313210332TRLO1.1.1

16/08/2022

10:54:24

416

242.5

XLON

00313210334TRLO1.1.1

16/08/2022

10:54:24

450

242.5

XLON

00313210333TRLO1.1.1

16/08/2022

10:54:24

59

242.5

CHIX

00313210330TRLO1.1.1

16/08/2022

10:54:24

482

242.5

XLON

00313210331TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210329TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210328TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210326TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210327TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210325TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210324TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210322TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210323TRLO1.1.1

16/08/2022

10:54:24

58

242.5

CHIX

00313210320TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210321TRLO1.1.1

16/08/2022

10:54:24

58

242.5

CHIX

00313210319TRLO1.1.1

16/08/2022

10:54:24

57

242.5

CHIX

00313210318TRLO1.1.1

16/08/2022

10:54:24

46

242.5

BATE

00313210317TRLO1.1.1

16/08/2022

10:54:24

49

242.5

BATE

00313210316TRLO1.1.1

16/08/2022

10:54:24

49

242.5

BATE

00313210314TRLO1.1.1

16/08/2022

10:54:24

49

242.5

BATE

00313210315TRLO1.1.1

16/08/2022

10:54:24

50

242.5

BATE

00313210313TRLO1.1.1

16/08/2022

10:54:24

46

242.5

BATE

00313210312TRLO1.1.1

16/08/2022

10:54:24

5

242.5

TRQX

00313210311TRLO1.1.1

16/08/2022

10:54:24

59

242.5

CHIX

00313210309TRLO1.1.1

16/08/2022

10:54:24

45

242.5

TRQX

00313210310TRLO1.1.1

16/08/2022

10:54:24

62

242.5

CHIX

00313210307TRLO1.1.1

16/08/2022

10:54:24

64

242.5

CHIX

00313210308TRLO1.1.1

16/08/2022

10:54:24

52

242.5

CHIX

00313210306TRLO1.1.1

16/08/2022

10:54:24

32

242.5

AQXE

00313210305TRLO1.1.1

16/08/2022

10:54:24

28

242.5

AQXE

00313210304TRLO1.1.1

16/08/2022

10:54:24

31

242.5

AQXE

00313210303TRLO1.1.1

16/08/2022

10:54:24

30

242.5

AQXE

00313210302TRLO1.1.1

16/08/2022

10:54:24

28

242.5

AQXE

00313210300TRLO1.1.1

16/08/2022

10:54:24

30

242.5

AQXE

00313210301TRLO1.1.1

16/08/2022

10:54:24

49

242.5

BATE

00313210298TRLO1.1.1

16/08/2022

10:54:24

4

242.5

TRQX

00313210299TRLO1.1.1

16/08/2022

10:54:24

40

242.5

BATE

00313210296TRLO1.1.1

16/08/2022

10:54:24

51

242.5

BATE

00313210297TRLO1.1.1

16/08/2022

10:54:24

62

242.5

CHIX

00313210294TRLO1.1.1

16/08/2022

10:54:24

41

242.5

BATE

00313210295TRLO1.1.1

16/08/2022

10:54:24

41

242.5

BATE

00313210292TRLO1.1.1

16/08/2022

10:54:24

54

242.5

CHIX

00313210293TRLO1.1.1

16/08/2022

10:54:24

32

242.5

AQXE

00313210291TRLO1.1.1

16/08/2022

10:54:24

28

242.5

AQXE

00313210290TRLO1.1.1

16/08/2022

10:54:24

28

242.5

AQXE

00313210289TRLO1.1.1

16/08/2022

10:54:24

29

242.5

AQXE

00313210287TRLO1.1.1

16/08/2022

10:54:24

30

242.5

AQXE

00313210288TRLO1.1.1

16/08/2022

10:54:24

34

242.5

AQXE

00313210286TRLO1.1.1

16/08/2022

09:50:52

34

242.5

AQXE

00313197392TRLO1.1.1

16/08/2022

09:49:18

46

241.5

BATE

00313197093TRLO1.1.1

16/08/2022

09:49:07

516

242.5

XLON

00313197060TRLO1.1.1

16/08/2022

09:49:07

437

242.5

XLON

00313197061TRLO1.1.1

16/08/2022

09:49:07

57

242.5

CHIX

00313197059TRLO1.1.1

16/08/2022

09:49:07

57

242.5

CHIX

00313197058TRLO1.1.1

16/08/2022

09:49:07

46

242.5

BATE

00313197057TRLO1.1.1

16/08/2022

09:49:07

46

242.5

BATE

00313197056TRLO1.1.1

16/08/2022

09:49:07

29

242.5

AQXE

00313197055TRLO1.1.1

16/08/2022

09:38:57

693

242.5

XLON

00313195531TRLO1.1.1

16/08/2022

09:38:57

65

242.5

CHIX

00313195530TRLO1.1.1

16/08/2022

09:38:57

61

242.5

CHIX

00313195529TRLO1.1.1

16/08/2022

09:38:57

29

242.5

AQXE

00313195528TRLO1.1.1

16/08/2022

09:38:57

46

242.5

BATE

00313195527TRLO1.1.1

16/08/2022

09:38:57

46

242.5

BATE

00313195526TRLO1.1.1

16/08/2022

09:38:57

32

242.5

AQXE

00313195525TRLO1.1.1

16/08/2022

09:18:45

439

242

XLON

00313191509TRLO1.1.1

16/08/2022

09:15:29

64

242.5

CHIX

00313191089TRLO1.1.1

16/08/2022

09:14:32

44

242

BATE

00313190866TRLO1.1.1

16/08/2022

09:14:32

88

242

BATE

00313190865TRLO1.1.1

16/08/2022

09:14:31

32

242

AQXE

00313190863TRLO1.1.1

16/08/2022

09:13:13

468

242

XLON

00313190185TRLO1.1.1

16/08/2022

09:05:46

30

242

AQXE

00313188781TRLO1.1.1

16/08/2022

09:05:39

434

242

XLON

00313188770TRLO1.1.1

16/08/2022

09:05:24

56

242

CHIX

00313188733TRLO1.1.1

16/08/2022

09:01:01

29

242.5

AQXE

00313188009TRLO1.1.1

16/08/2022

08:54:23

76

241

XLON

00313186791TRLO1.1.1

16/08/2022

08:54:09

53

242.5

CHIX

00313186659TRLO1.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFIATAIRLIF
Date   Source Headline
10th Jun 20265:38 pmRNSResult of AGM
9th Jun 20267:00 amRNS-RPRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data
4th Jun 20265:37 pmRNSHolding(s) in Company
29th May 20265:00 pmRNSHolding(s) in Company
27th May 20265:30 pmRNSHolding(s) in Company
22nd May 20265:00 pmRNSHolding(s) in Company
15th May 20267:00 amRNSCorrection - Holding(s) in Company
13th May 202612:00 pmRNS-RPRTC To Showcase Deupirfenidone at ATS Conference
8th May 20267:00 amRNSHolding(s) in Company
7th May 20266:27 pmRNSHolding(s) in Company
1st May 20267:00 amRNSPureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
29th Apr 20267:01 amRNSFinal Results
29th Apr 20267:00 amRNSPRTC Voluntarily Delists Nasdaq Depositary Shares
27th Apr 20266:09 pmRNSHolding(s) in Company
27th Apr 202612:05 pmRNS-RPRTC's Seaport Adds Neuropsychiatry Veteran to BOD
24th Apr 20265:58 pmRNSHolding(s) in Company
22nd Apr 202612:00 pmRNS-RPRTC's Gallop: Positive Ph1 Topline MDS & AML Data
16th Apr 20265:00 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSHolding(s) in Company
13th Apr 20267:05 amRNSNotice of Results
13th Apr 20267:00 amRNSPRTC's Seaport Files for Proposed Nasdaq IPO
1st Apr 20267:00 amRNSTotal Voting Rights
25th Mar 20266:00 pmRNS-RPRTC’s Seaport: GlyphAllo Paper Published
13th Mar 20264:35 pmRNSPDMR Notification RSU Vesting
2nd Mar 20267:00 amRNSTotal Voting Rights
25th Feb 20267:00 amRNS-RPRTC to Present at Leerink Healthcare Conference
19th Feb 20265:15 pmRNS-RPRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 202612:00 pmRNS-RPureTech to Present at the JP Morgan Conference
18th Dec 20257:00 amRNSPureTech Appoints Robert Lyne as CEO
10th Dec 20255:41 pmRNSResults of AGM on June 16, 2025 – Update Statement
10th Dec 20255:30 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RPRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
5th Dec 20256:00 pmRNS-RPRTC's Gallop: Positive Initial Topline AML Data
18th Nov 20255:30 pmRNSHolding(s) in Company
7th Nov 20256:18 pmRNSHolding(s) in Company
3rd Nov 20252:00 pmRNS-RPRTC: New LYT-200 AML Data + Update at ASH
22nd Oct 20257:00 amRNS-RPRTC: New IPF Data Show Benefit in Older Patients
17th Oct 20255:30 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSHolding(s) in Company
10th Oct 20255:59 pmRNSHolding(s) in Company
9th Oct 20256:10 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
29th Sep 20257:00 amRNS-RPRTC: New IPF Data Show Switch Patients Stabilized
24th Sep 20257:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Sep 20255:30 pmRNSHolding(s) in Company
19th Sep 20255:52 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNSHolding(s) in Company
11th Sep 202512:05 pmRNS-RPRTC's Seaport Advances 2nd Candidate Into Clinic
4th Sep 20255:30 pmRNSHolding(s) in Company
1st Sep 20257:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.